Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Annals of Oncology

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdv571PMID 26598540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

  2015cited by this paper
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

  2015cited by this paper
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

  2015cited by this paper
• Clinical overview of metronomic chemotherapy in breast cancer

  2015cited by this paper
• Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC).

  2015cited by this paper
• New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

  2014cited by this paper
• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

  2014cited by this paper
• Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

  2014cited by this paper
• Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

  2013cited by this paper
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  2013cited by this paper
• Molecular Pathways Molecular Pathways : Involvement of ImmunePathways in the Therapeutic Response and Outcome in Breast Cancer

  2012cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

  2011cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Immune infiltration in human tumors: a prognostic factor that should not be ignored

  2010cited by this paper
• Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

  2010cited by this paper
• American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination

  2009cited by this paper
• The anticancer immune response: indispensable for therapeutic success?

  2008cited by this paper
• Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper
• Statistical methods for assessing agreement between two methods of clinical measurement.

  1986cited by this paper

• Tumor PD-L1 induces β2m ubiquitylation and degradation for cancer cell immune evasion

  2026cites this paper
• Discordance of Radiologic and Pathologic Complete Response in Patients with Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

  2025cites this paper
• Predictive and prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a real-world study from Vietnam

  2025cites this paper
• Targeting the tumor microenvironment in triple-negative breast cancer: Biological insights and therapeutic opportunities.

  2025cites this paper
• Immunotherapy and combination treatments for triple-negative breast cancer: a Scopus bibliometric perspective.

  2025cites this paper
• Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer

  2025cites this paper
• PML localization in tumor associated macrophages as a prognostic marker in triple negative breast cancer

  2025cites this paper
• Harnessing Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Opportunities and Barriers to Clinical Integration

  2025cites this paper
• Comparative survival outcomes of neoadjuvant and adjuvant therapy in patients with T1c, node-negative, triple-negative breast cancer: A population-based analysis

  2025cites this paper
• In triple-negative breast cancer, fibrotic focus, the mitotic activity index and tumour-infiltrating lymphocytes have independent prognostic value: an observational population-based cohort study with very long follow-up

  2025cites this paper
• Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma.

  2024cites this paper
• Ferroptotic Neutrophils Induce Immunosuppression and Chemoresistance in Breast Cancer

  2024cites this paper
• Luteolin exerts anti‐tumour immunity in hepatocellular carcinoma by accelerating CD8 + T lymphocyte infiltration

  2024cites this paper
• Association of clinicopathologic and sonographic features with stromal tumor-infiltrating lymphocytes in triple-negative breast cancer

  2024cites this paper
• Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer

  2024cites this paper
• [Tumor infiltrating lymphocytes (TILs) in triple negative breast cancer].

  2024cites this paper
• The therapeutic role of γδT cells in TNBC

  2024cites this paper
• Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

  2024cites this paper
• Clinical and radiomics integrated nomogram for preoperative prediction of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer

  2024cites this paper
• Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade

  2024cites this paper
• Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges

  2023cites this paper
• Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives

  2023cites this paper
• Prognostic predictive value of Ki-67 in stage I–II triple-negative breast cancer

  2023cites this paper
• The Value of Tumor Infiltrating Lymphocytes (TIL) for Predicting the Response to Neoadjuvant Chemotherapy (NAC) in Breast Cancer according to the Molecular Subtypes

  2023cites this paper
• Construction of immune score and its prognostic value in invasive lobular carcinoma of the breast using computational pathology analysis

  2023cites this paper
• Prognostic relevance of tumor‑infiltrating lymphocytes in residual tumor tissue from patients with triple‑negative breast cancer following neoadjuvant chemotherapy: A systematic review and meta‑analysis

  2023cites this paper
• Characterization and Spatial Distribution of the Immune Cell Infiltrate in Triple-Negative Breast Cancer: A Novel Classification based on Plasma Cells and CD8+ T cells.

  2023cites this paper
• Interleukin 17 in early invasive breast cancer

  2023cites this paper
• The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1/Balb/c mouse model of stage four breast cancer

  2023cites this paper
• Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer

  2023cites this paper
• RhoB as a tumor suppressor: It's all about localization.

  2023cites this paper
• A pathomic approach for tumor-infiltrating lymphocytes classification on breast cancer digital pathology images

  2023cites this paper
• Artificial intelligence‐based digital scores of stromal tumour‐infiltrating lymphocytes and tumour‐associated stroma predict disease‐specific survival in triple‐negative breast cancer

  2023cites this paper
• Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer

  2022cites this paper
• Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors

  2022cites this paper
• Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer

  2022cites this paper
• Stromal Tumor Infiltrating Lymphocytes (sTILs) Were Associated with a Higher Grade and a Lower Stage of Indonesian Triple Negative Breast Cancers

  2022cites this paper
• Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages

  2022cites this paper
• Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer

  2022influential citation
• The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer

  2022cites this paper
• Research progress on immunotherapy in triple-negative breast cancer (Review)

  2022cites this paper
• PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers

  2022cites this paper
• Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes

  2022cites this paper
• Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer

  2022cites this paper
• Stem Cell Marker Aldehyde Dehydrogenase 1A1 Expression in Triple-negative Breast Carcinoma

  2022cites this paper
• Clinico-pathological relationship between androgen receptor (AR) and tumor in�ltrating lymphocytes (TILs) in triple negative breast cancer (TNBC)

  2021cites this paper
• A clinical calculator to predict disease outcomes in women with triple-negative breast cancer

  2021cites this paper
• Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer

  2021cites this paper
• RNA expression classifiers from a model of breast epithelial cell organization to predict pathological complete response in triple negative breast cancer

  2021cites this paper
• CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer

  2021cites this paper
• Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer

  2021cites this paper
• T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models

  2021cites this paper
• Triple Negative Breast Cancer

  2021cites this paper
• Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

  2021cites this paper
• Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer

  2021cites this paper
• Group 2 innate lymphoid cells promote TNBC lung metastasis via the IL-13-MDSC axis in a murine tumor model.

  2021cites this paper
• A Computational Tumor-Infiltrating Lymphocyte Assessment Method Comparable with Visual Reporting Guidelines for Triple-Negative Breast Cancer

  2021cites this paper
• CDKN1C as a prognostic biomarker correlated with immune infiltrates and therapeutic responses in breast cancer patients

  2021cites this paper
• Development and Validation of a Novel Model for Predicting Prognosis of Non-PCR Patients After Neoadjuvant Therapy for Breast Cancer

  2021cites this paper
• Assessment of programmed death-ligand 1 receptor immunohistochemical expression and its association with tumor-infiltrating lymphocytes and p53 status in triple-negative breast cancer

  2021cites this paper
• Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer

  2021influential citation
• Nomogram to Predict Tumor-Infiltrating Lymphocytes in Breast Cancer Patients

  2021cites this paper
• Prognostic value of tumor-in ltrating lymphocytes in patients with triple- negative breast cancer: a systematic review and meta-analysis

  2021influential citation
• Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis

  2020cites this paper
• Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

  2020cites this paper
• Reporting Core Biopsies: Lesions That Are Highly Suspicious of Malignancy (B4) or Definitely Malignant (B5)

  2020cites this paper
• Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer

  2020cites this paper
• Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer

  2020cites this paper
• Evaluation of tumour infiltrating lymphocytes in core needle biopsies and resected specimens of breast carcinoma

  2020cites this paper
• Association between levels of tumor-in ltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: A meta-analysis

  2020cites this paper
• Development and validation of a seven‐immune‐feature‐based prognostic score for oral squamous cell carcinoma after curative resection

  2020influential citation
• Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer

  2020cites this paper
• Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis

  2020cites this paper
• Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple‐negative breast cancer

  2020cites this paper
• Local and Systemic Inflammatory Markers as Prognostic and Predictive Markers In Locally Advanced Triple Negative Breast Cancer

  2020cites this paper
• Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer.

  2020cites this paper
• Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases.

  2020cites this paper
• Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features.

  2020cites this paper
• Clinicopathologic Characteristics of Breast Cancer According to the Infiltrating Immune Cell Subtypes

  2020cites this paper
• Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy

  2020cites this paper
• Stromal Tumor Infiltrating Lymphocytes (sTILs) as a putative prognostic marker to identify a responsive subset of TNBC in an Indian Breast Cancer Cohort.

  2020cites this paper
• Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer

  2019cites this paper
• Diagnostik und Therapie des triple-negativen Mammakarzinoms (TNBC) – Empfehlungen für die tägliche Routine

  2019cites this paper
• Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

  2019cites this paper
• Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer

  2019cites this paper
• Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy

  2019cites this paper
• Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis

  2019cites this paper
• Association between the elevation of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: A meta-analysis

  2019cites this paper
• Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

  2019cites this paper
• Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology

  2019cites this paper
• Hotspot enumeration of CD8+ tumor-infiltrating lymphocytes using digital image analysis in triple-negative breast cancer yields consistent results.

  2019cites this paper
• Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study

  2019cites this paper
• BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.

  2019cites this paper
• Cytological tumour cell characteristics and reactive small lymphocytes influence patient prognosis in acute and lymphoma type adult T‐cell leukaemia/lymphoma

  2019cites this paper
• Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes

  2019cites this paper
• T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer

  2019cites this paper
• Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor Infiltrating Lymphocytes in Invasive Breast Cancer

  2019cites this paper
• Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

  2019cites this paper
• Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer

  2019cites this paper
• Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice

  2019cites this paper